Completed PHASE2 INTERVENTIONAL NCT00271349

Budesonide for Eosinophilic Esophagitis (BEE)

Budesonide for Eosinophilic Esophagitis: a Randomized, Placebo-controlled, Double-blind Treatment Study

Sponsor: Swiss EE Study Group

Interventions Budesonide

Updated 5 times since 2017 Last updated: May 21, 2015 Started: Dec 31, 2005 Primary completion: Jul 31, 2008 Completion: Dec 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00271349, this PHASE2 trial focuses on Eosinophilic Esophagitis and remains completed. Sponsored by Swiss EE Study Group, it has been updated 5 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Dec 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Swiss EE Study Group

Data source: Swiss EE Study Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Olten, Switzerland